uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapykatie8288Jun 23, 20220 min read
Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and other select markets
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Comments